Acorda Therapeutics, Inc.
- UEI
- R5D3FUPFFPK4
- CAGE
- 305Q1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- acorda.com
- Founded
- 1995
- Employees
- 51-250
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $938,112 |
| FY2023 | $529,877 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Amylyx Pharmaceuticals Inc. | — | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| U.s. Division | Rockville, MD | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Lundbeck LLC | Deerfield, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Genzyme | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Acorda Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of therapies for neurological disorders. The company has been a registered vendor with the U.S. federal government since September 2004 and has received multiple federal contract and grant awards. Acorda primarily supplies pharmaceutical products to federal agencies, with a focus on medications used to treat Parkinson's disease and multiple sclerosis. The company's main federal customer is the Department of Veterans Affairs (VA), which procures Acorda's products to provide high-quality healthcare to veterans suffering from neurological conditions.
Through its federal contract awards, Acorda Therapeutics has consistently provided the VA with Levodopa 42mg inhalation capsules, a medication used to treat Parkinson's disease symptoms. The company has received numerous delivery orders from the VA Veterans Health Administration, particularly through Veterans Integrated Service Network 12, for the supply of these capsules. The contract values have ranged from approximately $42,000 to over $500,000 per order. Additionally, Acorda supplies other neurological medications, including Inbrija for managing motor symptoms in Parkinson's disease and Ampyra for improving mobility in multiple sclerosis patients. These contracts are typically awarded as firm fixed-price delivery orders without set-aside designations, indicating that Acorda competes on an unrestricted basis.
Acorda Therapeutics holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that facilitate the procurement of its products by federal agencies. The company has a Federal Supply Schedule contract (36F79723D0194) with the VA, valued at over $16.3 million, for the supply of drugs, pharmaceuticals, and hematology-related products through September 2024. This multiple-award contract serves as the parent vehicle for many of the delivery orders Acorda receives. Additionally, the company has been awarded two Blanket Purchase Agreements (BPAs) by the VA National Acquisition Center. One BPA (36E79724A0005), valued at $5.5 million, and another (36E79723A0011), valued at $7.5 million, are specifically for the procurement of Inbrija and Ampyra. These BPAs provide a streamlined process for VA medical facilities nationwide to order Acorda's neurological medications, supporting the agency's mission to provide quality healthcare to veterans.
Quick answers
Is Acorda Therapeutics, Inc. registered in SAM.gov?
Acorda Therapeutics, Inc.'s SAM.gov registration expired on September 12, 2024.
Which contract vehicles does Acorda Therapeutics, Inc. hold?
Acorda Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Acorda Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $1,467,989 to Acorda Therapeutics, Inc. in fiscal years 2023 through 2027.
What is Acorda Therapeutics, Inc.'s most recent federal award?
Acorda Therapeutics, Inc.'s most recent federal contract award is Levodopa 42MG inhl 60/BT (36C77024N0067), from Veterans Integrated Service Network 15 (VHA), on May 21, 2024.
On GovTribe
See Acorda Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors